

Reversion of resistance to oxaliplatin by inhibition of p38 MAPK in colorectal cancer cell lines: Involvement of the calpain / Nox1 pathway


SUPPLEMENTARY MATERIALS




Supplementary Figure 1: Determination of the resistance status of selected cells. RKO, RKO-Rox1 (Rox1) and RKO-Rox2 (Rox2) were submitted to 72-hour cytotoxicity assays to oxaliplatin (A). The IC50 were calculated using the Chou and Talalay's method (B). Asteriks indicate a statistical significance with p < 0.05.




Supplementary Figure 2 : Evolution of spheroid area during 15-day cytotoxicity assays. HT29-D4, Rox1 and Rox2 were seeded in 96-well plates in a medium with 20% of methylcellulose. After a 72-hour incubation allowing the spheroid formation, the cells were treated with increasing concentrations of oxaliplatin (from 0.25 μ M to 100 μ M). The area were measured every two days for HT29-D4 (A), Rox1 (B) and Rox2 (C).



Supplementary Figure 3 : Expression of the components of Nox1 complex. The expressions of Nox1 (A), NoxO1 (B) and NoxA1 (C) were quantified from the bands obtained by Western blotting. Asteriks indicate a statistical significance with p < 0.05.



Supplementary Figure 4 : Sensitive and resistant RKO cells behave as sensitive and resistant HT29-D4. RKO, RKO-Rox1 and RKO-Rox2 cells were seeded in white 96-well plates to perform lucigenin assays in the absence (Control) or in the presence of oxaliplatin (A). RKO, RKO-Rox1 and RKO-Rox2 cells were seeded in black 96-well plates to perform calpain activity assays in the absence (Control) or in the presence of oxaliplatin (B). RKO, RKO-Rox1 and RKO-Rox2 cells were transfected with control siRNA (si Control), calpain 1 specific siRNA (si Calpain 1), calpain 2 specific siRNA (si Calpain 2) or both siRNAs (si Calpain 1/2). The cells were seeded in white 96-well plates to perform lucigenin assays (C). Asteriks indicate a statistical significance with p<0.05.



Supplementary Figure 5: Expression and activity of the ubiquitous calpains. The expressions of calpain 1 (A) and calpain 2 (B) were quantified from the bands obtained by Western blotting. HT29-D4, Rox1 and Rox2 cells were transfected with control siRNA or with siRNAs directed against calpain 1 and/or calpain 2. The cells were seeded on black 96-well plates and calpain activity was measured using t-boc. The activity was expressed as a percentage (C). Asteriks indicate a statistical significance with p<0.05.

А **Cleavage Site Predictions** Sequence: NADPH oxidase activator 1 OS=Homo sapiens GN=NOXA1 PE=1 SV=1 10 Best scores: Pos. 460 - Score: 1.99 Pos. 184 - Score: 1.67 1. 2. Pos. **184** - Score: 1.o/ 3. Pos. **402** - Score: 1.56 4. Pos. **283** - Score: 1.11 5. Pos. **266** - Score: 0.87 6. Pos. **276** - Score: 0.77 7. Pos. **473** - Score: 0.77 8. Pos. **230** - Score: 0.55 9. Pos. **267** - Score: 0.52 10. Pos. **206** - Score: 0.46 1 MAS LOD LY RAW HE GA DAY DRODWARA LHEFS GY PAPPAREC FRA GCY HELA OD PEAALRA FD DA YTK DT CRAY OFF DROY 81 A NEQLAREQUALSOFW LA LEOLROHAA I DYTOLOLREKLOAWEV LHNVA SAOCOLOLWT BAASS LR BAMSKWP BOSLNOL 101 DSALDQV QRAQSL FFR QV FRQEV FR FHRWHLK HLEFV DFLOKAK VVASA I FDDQ OWOVR FQQ FQ O FQA NHDARSL I MDS F OPCEDPA DA DOA DA DOS EPLVTVTVOC HOOPLOAET 321 A FTVA LRARROADLSS LRA LLOQA LPHOAOLOOLSY LA POEDOHWY PIPEEES LORAWODAAAC PROLOLOCROAOOR PV 401 A O MSY SA DO PED LOFROODTY DY LCEY DOAW LEO HCDOR I O I F PKC FYY PA OPRMS OA POR LPRS Rac gp91phox NoxO1 B NoxA1 H₂N TPR TPR TPR TPR PB1 SH3 COOH AD NoxA1-DDK H₂N DDK TPR TPR TPR TPR AD PB1 SH3 COOH Cleaved NoxA1-DDK PB1 S. 3 COOH H_2N DDK TPR TPR TPR TPR TPR AD

Supplementary Figure 6: NoxA1 is cleaved by calpains in its C-terminal part. Calpain cleavage of NoxA1 was predicted using SVM prediction model (on http://calpain.org/predict.rb?cls=substrate). The cleavage was predicted to occur at the C-terminal end of NoxA1 (A), in the SH3 domain, known to be involved in the interaction with NoxO1 (B).

| Α | 133 | (4.4.1) | Number | Target | Phosphorylation Site | Modification |
|---------------|--------------|--------------|--------|----------------------|----------------------|-----------------|
| | (5)(5)(6) | (677) | 1 | Positive Control | N/A | N/A |
| | 889 | 91010 | 2 | Negative Control | N/A | N/A |
| | (1)(1)(1) | (12)(13)(13) | 3 | ERK1/2 | Ther202/Tyr204 | Phosphorylation |
| | 141415 | 151616 | 4 | Stat1 | Tyr701 | Phosphorylation |
| | (17)(17)(18) | 18(19)(19) | 5 | Stat3 | Tyr705 | Phosphorylation |
| | 12020 | (2)(2)(2) | 6 | Akt | Thr308 | Phosphorylation |
| | | | 7 | Akt | Ser473 | Phosphorylation |
| | | | 8 | ΑΜΡΚα | Thr172 | Phosphorylation |
| B LOHP | - | + | 9 | S6 Ribosomal Protein | Ser235/236 | Phosphorylation |
| | | | 10 | mTOR | Ser2448 | Phosphorylation |
| HT29-D4 | | | 11 | HSP27 | Ser78 | Phosphorylation |
| | • | | 12 | Bad | Ser112 | Phosphorylation |
| | | | 13 | p70 S6 Kinase | Thr389 | Phosphorylation |
| | • • | • • | 14 | PRAS40 | Thr246 | Phosphorylation |
| Rox1 | 0000 | | 15 | p53 | Ser15 | Phosphorylation |
| | 0 | | 16 | p38 | Thr180/Thr182 | Phosphorylation |
| | | | 17 | SAPK/JNK | Thr183/Tyr185 | Phosphorylation |
| | | | 18 | PARP | Asp214 | Cleavage |
| Rox2 | 0000 | | 19 | Caspase-3 | Asp175 | Cleavage |
| | 0 | • | 20 | GSK-3β | Ser9 | Phosphorylation |

Supplementary Figure 7: Signaling pathway study using PathScan Array. Target map of PathScan Array allowing the simultaneous detection of 18 important and well-characterized signaling molecules when phosphorylated or cleaved (A). HT29-D4, Rox1 and Rox2 cells were seeded in 6-well plates and were incubated in the absence or in the presence of oxaliplatin for 24 hours. The cells were then lysed and 37.5 µg of cellular proteins were used for the PathScan assay. The raw data were obtained using the G box imaging system (B).

www.impactjournals.com/oncotarget/

Oncotarget, Supplementary Materials 2017

Α

| n* | Protein kinase name | Specificity score | Normalized kinase statistic |
|----|---------------------|-------------------|-----------------------------|
| 1 | p38g MAPK (MAPK12) | 2.7 | 0.42 |
| 2 | p38b MAPK (MAPK11) | 2.7 | 0.42 |
| 3 | p38a MAPK (MAPK14) | 2.7 | 0.42 |
| 4 | CHED | 2.7 | 0.5 |
| 5 | JNK3 (MAPK10) | 2.7 | 0.43 |
| 6 | JNK2 (MAPK9) | 2.7 | 0.43 |
| 7 | JNK1 (MAPK8) | 2.7 | 0.43 |
| 8 | p38d MAPK (MAPK13) | 2.5 | 0.39 |
| 9 | ERK5 (MAPK7) | 2.4 | 0.4 |
| 10 | ERK2 (MAPK1) | 1.7 | 0.36 |
| 11 | ERK1 | 1.7 | 0.36 |
| 12 | MAK | 1.6 | 0.65 |
| 13 | CDK3 | 1.4 | 0.41 |
| 14 | CDK1 (CDC2) | 1.4 | 0.41 |
| 15 | ATR | 0.8 | 0.34 |

B

| n° | Protein kinase name | Specificity score | Normalized kinase statistic |
|----|---------------------|-------------------|-----------------------------|
| 1 | p38g MAPK (MAPK12) | 1.4 | 0.6 |
| 2 | p38d MAPK (MAPK13) | 1.4 | 0.57 |
| 3 | PRKY | 1.1 | 0.57 |
| 4 | GSK3A | 1 | 0.53 |
| 5 | NDR2 (KIAA0965 | 0.9 | 0.57 |
| 6 | PRKX | 0.8 | 0.48 |
| 7 | p70S6Kb (RPS6KB2) | 0.8 | 0.48 |
| 8 | DNAPK/PRKDC | 0.8 | 0.56 |
| 9 | CHK2 (CHEK2) | 0.6 | 0.48 |

| | 7 | |
|---|---|--|
| C |) | |
| | | |

| n° | Protein kinase name | Specificity score | Normalized kinase statistic |
|----|---------------------|-------------------|-----------------------------|
| 1 | p38d MAPK (MAPK13) | 2.4 | 0.34 |
| 2 | p38b MAPK (MAPK11) | 2.0 | 0.39 |
| 3 | p38a MAPK (MAPK14) | 1.8 | 0.41 |
| 4 | JNK3 (MAPK10) | 1.8 | 0.39 |
| 5 | JNK2 (MAPK9) | 1.8 | 0.39 |
| 6 | JNK1 (MAPK8) | 1.8 | 0.39 |
| 7 | p38g MAPK (MAPK13) | 1.8 | 0.36 |
| 8 | ERK5 (MAPK7) | 1.8 | 0.35 |
| 9 | ERK1 | 1.6 | 0.29 |
| 10 | CHED | 1.5 | 0.46 |
| 11 | ERK7 (BI916334) | 1.4 | 0.70 |
| 12 | ATR | 1.4 | 0.41 |
| 13 | CDK2 | 1.2 | 0.30 |
| 14 | CDK3 | 1.0 | 0.32 |
| 15 | CDK1 (CDC2) | 1.0 | 0.35 |

Supplementary Figure 8: Comparison of serine/threonine kinase activities in Rox1 treated with oxaliplatin. Rox1 cells were seeded in 6-well plate and treated with 2 μ M of oxaliplatin during 45 minutes, 4 hours and 24 hours. The cells were lysed and 0.5 μ g of cellular protein were processed using the Pamgene kinase activity assay. The kinase activities of untreated and treated Rox1 cells were compared. The kinases presenting the strongest modifications after 45 minutes, 4 hours and 24 hours of treatment are presented in (A, B and C), respectively. A positive normalized kinase statistic indicates a kinase activity increased by oxaliplatin treatment.